期刊文献+

新疆维吾尔族原发性高血压与CYP11B2基因-344T/C多态性的关联性 被引量:3

Association of the-344T/C polymorphism of aldosterone synthase gene CYP11 B2 with essential hypertension in Xinjiang uygur isolated group
下载PDF
导出
摘要 目的:探讨维吾尔族人群原发性高血压与醛固酮合成酶基因(CYP11B2)-344T/C多态性的关联性。方法:采用聚合酶链反应、限制性片段长度多态性的方法,检测新疆和田地区维吾尔族233例原发性高血压患者(高血压组)和252例正常人群(对照组)醛固酮合成酶基因(CYP11B2)-344T/C多态性。结果:维吾尔族正常人群及高血压患者的-344T/C基因多态性CC、TT、TC基因型频率分布分别为0.167、0.401、0.433和0.155、0.386、0.459,C和T等位基因分布频率分别为0.383、0.617和0.384、0.616,符合Hardy-Weinberg平衡。高血压组与对照组CYP11B2基因-344T/C的C及T等位基因分布差异无统计学意义(χ2=0.001,P=0.97),基因型频率差异无统计学意义(χ2=0.370,P=0.831)。结论:新疆和田地区维吾尔族原发性高血压与CYP11B2基因-344T/C多态性无关联。 Objective: To investigate the association of the -344T/C polymorphism of aldosterone synthase gene CYPllB2 with essential hypertension in Xinjiang Uygur isolated population. Methods: The study covered 233 hypertensive and 252 normotensive controls in Xinjiang Uygur population. The segment of CYPllB2 was amplified from DNA by polymerase chain reaction (PCR). The PCR products were digested by restriction endonuclease. Result: The frequencies of C and T in hypertensive group (0. 384 and 0. 616) were not significantly different from those in the control group (0. 383 and 0. 617; x^22=0. 001, P =0.97). The frequencies of-344T/C genotypes of CC, TT and TC were 0. 155, 0. 386and 0. 459 in hypertensive respectively, and 0. 167, 0. 401and 0. 433 in controls respectively. There was no significant difference in genotype between hypertensive group and normotensive group (x^2=0. 370, P =0. 831). Conclusion: The result suggested that the -344T/C polymorphism of CYPllB2 gene may not be associated with hypertension in Uygur population of Xinjiang.
作者 李静 徐新娟
出处 《新疆医科大学学报》 CAS 2008年第4期443-445,共3页 Journal of Xinjiang Medical University
基金 新疆维吾尔自治区自然科学基金项目(200421123)
关键词 高血压病 维吾尔族 醛固酮合成酶基因 基因多态性 hypertension uygur aldosterone synthase gene CYP11B2 gene polymorphism
  • 相关文献

参考文献10

二级参考文献38

  • 1刘丽娟,叶宏,佟伟军,刘国玉,李永山,黄桂蓉,王健,张永红.蒙古族高血压者血管紧张素转换酶基因多态性与胰岛素抵抗及血脂的关系(英文)[J].中国临床康复,2004,8(33):7585-7587. 被引量:1
  • 2Stamler J, Stamler R, Neaton JD, et al. Blood pressure, systolic and diastolic, and cardiovascular risks, CLS population data [J]. Arch InternMed, 1993,153(5) :598-615.
  • 3Tomita N, Morishita R, Higaki J, et al. Transient decrease in high blood pressure by in vivo transfer of antisense oligodeoxynucleotides against rat ana'iotensinozen[ J]. Hvvertension, 1995,26( 1 ) : 131-136.
  • 4Gyurko R,Wielbo D, Phillips MI. Antisense inhibition of AT, receptor mRNA and anglotensin mRNA in the brain of spontaneously hypertensive rats reduces hypertension of neurogenie origin[J].Regul Pept,1993,49(2):167-174.
  • 5Phillips MI, Wielbo D, Gyurko R. Antisense inhibition of hypertension anew strategy for renin-angiotensin candidate genes [J]. Kidney Int,1994,46(6) : 1554-1556.
  • 6Ambuhl P, Gyurko R, Phillips MI. A decrease in angiotensin receptor binding in rat brain nuclei by antisense oligonucleotides to the anglotensin AT1 receptor[J]. Regul Pept, 1995,59(2) : 171-182.
  • 7Mohan K, Sharon C, Wang H, et al.Targeting of the renin-angiotcnsin system by antisense gene therapy: a possible strategy for the tong-trem control of hypertension [J]. Hypertension, 2000,18 (4) : 352-362.
  • 8Wang H, Reaves PY, Gardon ML, et ol. Angiotensin l-converting enzyme antisense gene therapy causes permanent antihypertensive effects in the SHR [J]. Hvoertension, 2000,35 ( 1 ) : 202-208.
  • 9Phillips MI, Mohuezy-Dominiak D, Coffey M, et al. Prolonged reduction of high blood pressure with an in vivo, nonpathogenic, adeno-associated viral vector delivery of AT1 R mRNA antisense[ J]. Hypertension, 1997,29( 1 Pt 2) :374-380.
  • 10Raizada MK, Katovich MJ, Wang H, et al. Is antisense gene therapy a step in the right direction in the control of hypertension[J]. Am J Physiol, 1999,277 (2) : H423-432.

共引文献90

同被引文献60

引证文献3

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部